{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:04:44Z","timestamp":1762211084566,"version":"3.40.4"},"reference-count":6,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.omtn.2025.102476","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T10:14:36Z","timestamp":1739787276000},"page":"102476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["SNA-modified antisense oligonucleotides: A new pathway for renal targeting?"],"prefix":"10.1016","volume":"36","author":[{"given":"Bernhard","family":"Dumoulin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1005-3726","authenticated-orcid":false,"given":"Katalin","family":"Susztak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2025.102476_bib1","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1002\/anie.201006498","article-title":"Control of the chirality and helicity of oligomers of serinol nucleic acid (SNA) by sequence design","volume":"50","author":"Kashida","year":"2011","journal-title":"Angew. Chem., Int. Ed. Engl."},{"key":"10.1016\/j.omtn.2025.102476_bib2","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1039\/D1CC05868A","article-title":"Xeno nucleic acids (XNAs) having non-ribose scaffolds with unique supramolecular properties","volume":"58","author":"Asanuma","year":"2022","journal-title":"Chem. Commun."},{"key":"10.1016\/j.omtn.2025.102476_bib3","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1002\/cbic.201700272","article-title":"Introduction of 2,6-diaminopurines into serinol nucleic acid improves anti-miRNA performance","volume":"18","author":"Kamiya","year":"2017","journal-title":"Chembiochem"},{"key":"10.1016\/j.omtn.2025.102476_bib4","doi-asserted-by":"crossref","first-page":"34049","DOI":"10.1039\/C7RA06091B","article-title":"Antisense oligonucleotide modified with serinol nucleic acid (SNA) induces exon skipping in mdx myotubes","volume":"7","author":"Le","year":"2017","journal-title":"RSC Adv."},{"key":"10.1016\/j.omtn.2025.102476_bib5","doi-asserted-by":"crossref","first-page":"102387","DOI":"10.1016\/j.omtn.2024.102387","article-title":"In\u00a0vivo efficacy and safety of systemically administered serinol nucleic acid-modified antisense oligonucleotides in mouse kidney","volume":"36","author":"Tsuboi","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2025.102476_bib6","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1016\/j.ymthe.2022.04.007","article-title":"Antisense oligonucleotides ameliorate kidney dysfunction in podocyte-specific APOL1 risk variant mice","volume":"30","author":"Yang","year":"2022","journal-title":"Mol. Ther."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125000307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125000307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T01:37:29Z","timestamp":1744508249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253125000307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":6,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2162253125000307"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102476","relation":{},"ISSN":["2162-2531"],"issn-type":[{"type":"print","value":"2162-2531"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SNA-modified antisense oligonucleotides: A new pathway for renal targeting?","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102476","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102476"}}